Renascience, a drug discovery biotech originated from Tohoku University, and ASKA Pharmaceutical have entered into an exclusive option agreement for RS8001 (pyridoxamine), the smaller company’s investigational treatment for premenstrual syndrome accompanied by psychological symptoms and premenstrual dysphoric disorder, they said…
To read the full story
Related Article
- ASKA, Renascience Wind Up PMS Drug Collab after PII Miss
November 26, 2024
BUSINESS
- Takeda Swings to Loss after Booking Amitiza Litigation Charge
June 8, 2026
- GNI to Acquire Ayumi Pharma in 44.8 Billion Yen Deal
June 8, 2026
- Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026
- Kaken Files Head Lice Treatment in Japan
June 8, 2026
- UCB Japan Seeks Pediatric Use, Dry Syrup Approval for Briviact
June 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





